NIH pre-clinical screening program: overview and current status
NIH pre-clinical screening program: overview and current status
复制标题
DOI：
10.1016/j.tube.2004.09.008
复制
发表时间：
2005-01-01
期刊：
影响因子：
3.2
通讯作者：
Orme, I
中科院分区：
文献类型：
--
作者：
Izzo, A;Brandt, L;Orme, I
世界各地结核分枝杆菌病例数量的增加导致对比目前使用的牛分枝杆菌卡介苗更有效的疫苗的更大需求。尽管这种减毒疫苗取得了相对的成功，但在许多例子中，迫切需要其他战略。1996年，美国国立卫生研究院（National Institutes of Health）发布了一项申请，要求对新开发的结核病疫苗进行测试。科罗拉多州立大学目前的筛选项目已经测试了大量的新型候选疫苗。(C) 2004 Elsevier Ltd.版权所有。
The increase in the number of cases of Mycobocterium tuberculosis around the world has lead to a greater need for a more efficacious vaccine than the currently used M. bovis BCG. Despite the relative success of this attenuated vaccine there are multiple examples where alternative strategies are desperately needed. In 1996, the National Institutes of Health published a request calling for applications to test newly developed vaccines against tuberculosis. The current screening program at Colorado State University has tested a wide range of novel vaccine candidates. (C) 2004 Elsevier Ltd. All rights reserved.